Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2025-12-29 @ 4:00 AM
Study NCT ID:
NCT04743804
Status:
TERMINATED
Last Update Posted:
2024-10-01
First Post:
2021-01-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
Sponsor:
Alexion Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-29
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-22
Completion Date Type:
ACTUAL
First Submit Date:
2021-01-28
First Submit QC Date:
None
Study First Post Date:
2021-02-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-11-21
Results First Submit QC Date:
None
Results First Post Date:
2023-12-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-16
Last Update Post Date:
2024-10-01
Last Update Post Date Type:
ACTUAL